Direct Oral Anticoagulants Plasma Levels in Patients with Atrial Fibrillation at the Time of Bleeding: A Pilot Prospective Study

Patients with atrial fibrillation (AF) on long-term direct oral anticoagulants (DOACs) may be at higher risk of bleeding because of higher anti-Xa or anti-lla levels. However, there is no postmarketing study investigating these DOAC plasma levels at the time of bleeding. The aim of this study was to evaluate DOAC levels at the time of a bleeding emergency. We analyzed 5440 patients examined at our Emergency Department in from April 1, 2019, to September 30, 2019. During this period, we prospective identified 105 consecutive patients with bleeding while on long-term antithrombotic therapy; 49 patients had AF on DOACs. We compared DOAC levels in patients who bled against a control sample of 55 patients who tolerated long-term high dose DOAC therapy without any emergency. Samples of these patients were tested with drugspecific anti-Xa chromogenic analysis (rivaroxaban and apixaban) and with Hemoclot Thrombin Inhibitor assay (dabigatran). Dabigatran-treated patients who bled had significantly higher antiHa levels when compared with trough (261.4 +/- 163.7 vs. 85.4 +/- 57.2 ng/mL, P < 0.001) and peak samples of controls (261.4 +/- 163.7 vs. 138.8 +/- 78.7 ng/mL, P < 0.05). Similarly, there were significantly higher anti-Xa levels in rivaroxaban-treated and apixaban-treated patients with bleeding compared with trough control samples (rivaroxaban: 245.9 +/- 150.2 vs. 52.5 +/- 36.4 ng/mL, P <0.001 and apixaban: 311.8 +/- 142.5 vs. 119.9 +/- 81.7 ng/mL, P < 0.001), as well as in apixaban-treated patients when compared with peak control samples (311.8 +/- 142.5 vs. 210.9 +/- 88.7 ng/mL, P < 0.05). Finally, rivaroxaban anti-Xa levels in patients who bled tended to be higher compared with peak control samples (245.9 +/- 150.2 vs. 177.6 +/- 38.6 ng/mL, P = 0.13). This observational study showed a significant difference in anti-lla and anti-Xa plasma levels in patients with AF with bleeding complications compared with those who tolerated long-term high-dose DOAC therapy without bleeding complications.

Automated summary

This study revealed a significant difference in anti-IIa and anti-Xa plasma levels in patients with atrial fibrillation experiencing bleeding complications compared with those who tolerated long-term high-dose DOAC therapy without bleeding complications.